Vitamin B12 for Mood Stabilization

B12's link to mood runs through one-carbon metabolism. The vitamin is a required cofactor for methionine synthase, and that reaction produces S-adenosylmethionine, the universal methyl donor used in synthesising serotonin, dopamine and noradrenaline. Deficiency therefore constrains monoamine production at source, which is why low B12 status shows up repeatedly in depressed populations. What the evidence supports is correcting a deficit, not augmenting normal function.

The most useful framing comes from meta-analysis: supplementation shows benefit for depressive symptoms and fatigue chiefly in people with low or borderline B12 status, and adds little in replete individuals with normal levels. It is also better positioned as prevention of relapse and as an adjunct to treatment than as a standalone antidepressant, since correcting deficiency takes months to translate into neurological improvement.

Methylcobalamin serves methionine synthase, converting homocysteine to methionine and regenerating tetrahydrofolate. The methionine becomes S-adenosylmethionine, which donates methyl groups for the synthesis and degradation of monoamine neurotransmitters. Deficiency traps folate in an unusable form and raises homocysteine, a state independently associated with depressive symptoms.

Adenosylcobalamin, the second active form, supports methylmalonyl-CoA mutase in mitochondria. When this fails, methylmalonic acid accumulates and abnormal fatty acids are incorporated into myelin — the pathway behind the neurological and psychiatric presentations of severe deficiency, which can include irritability, apathy and, rarely, psychosis. Because myelin repair is slow, mood and cognitive recovery after repletion lags haematological correction by months.

Oral B12 works even in pernicious anaemia because a small fraction is absorbed by passive diffusion independent of intrinsic factor — which is why oral doses are set far above the physiological requirement. Methylcobalamin and hydroxocobalamin are reasonable choices; the older cyanocobalamin is cheaper and well studied.

The linked Nutrients systematic review, meta-analysis and meta-regression examined vitamin B12 supplementation across cognitive function, depressive symptoms and fatigue. It found benefit that depended heavily on baseline status: participants with low or borderline B12 improved, while those already replete showed little change, and combined B-vitamin protocols including folate performed better than B12 alone. The meta-regression is the most useful part for readers, because it makes explicit that the driver of effect is the size of the deficit being corrected. That is the difference between a treatment and a mood supplement, and this pairing sits firmly on the treatment side.

B12 is water-soluble with no established upper limit; excess is excreted renally and even gram-level oral doses are well tolerated. Occasional reports include mild acne or rosacea flares with high-dose cyanocobalamin, and rare injection-site reactions with parenteral forms.

The dominant issue is not toxicity but induced deficiency: several very common long-term medications reduce B12 absorption, which is a frequent and under-recognised cause of the low status this pairing is about.